ClinicalTrials.gg
TerminatedNCT05653427Updated Jan 13, 2025Results posted

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Amivantamab in Carcinoma, Hepatocellular, sponsored by Janssen Research & Development, LLC. Terminated at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
935th of 1,034
18 · median 78
Started
2022
with 110 others
Phase 2
331 of 1,310
144 open now
Registered
781st of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 935th largest by enrollment of the 1,034 interventional ones that give a count, is one of 111 that started in 2022, is one of 331 in phase 2, and was the 781st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC) (fibrolamellar and mixed hepatocellular / cholangiocarcinoma subtypes are not eligible) based on pathology report, who have barcelona clinic liver cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach
  • Participant must have according to response criteria in solid tumors () Version 1.1. Selected target lesions must meet 1 of 2 criteria: 1) not previously treated with local therapy or 2) within the field of prior local therapy but with documented subsequent progression as per RECIST v1.1
  • Participant must have (ECOG) performance status 0 or 1
  • Participant must have adequate organ and bone marrow function
  • A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Female participants should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility

Exclusion criteria

Exclusion Criteria:

  • Participants with prior liver transplant, history of hepatic encephalopathy, portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging, or any current moderate or severe ascites as measured by physical examination that requires active paracentesis for control due to the underlying HCC
  • Participant has known allergies, , or intolerance to of amivantamab
  • Participant has received a live or within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary
  • Other clinically active liver disease of infectious origin
  • Participant has a history of cardiovascular disease including, but not limited to: a. diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study treatment or any of the following within 6 months prior to the first dose of study treatment: myocardial infarction, unstable angina, stroke, , coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as nonobstructive catheter-associated clots, are not exclusionary; b. prolonged interval using Fridericia's formula (QTcF) greater than (>)480 millisecond (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); c. uncontrolled (persistent) hypertension: systolic blood pressure >160 mm Hg; diastolic blood pressure >100 millimeter of mercury (mm Hg), or congestive heart failure (CHF) defined as (NYHA) class III/IV or hospitalization for CHF (any NYHA class) within 6 months of study enrollment; d. pericarditis/clinically significant pericardial effusion; e. myocarditis
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Amivantamab Monotherapy

    Participants will receive amivantamab monotherapy intravenously once weekly on Days 1 and 2 in Cycle 1 and on Days 1 and 15 from Cycle 2 onwards based on body weight. Each cycle is of 28 days.

    Drug: Amivantamab

Interventions

  • Amivantamab will be administered intravenously.

    Also known as: JNJ-61186372

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment

    ORR was defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) as determined by investigator per RECIST version 1.1. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to less than (\<)10 millimeter (mm) short axis and the normalization of tumor marker level. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions.

    Time frame: From start of treatment on Day 1 up to 3.8 months

Secondary outcomes

  1. Duration of Response (DOR) as Per RECIST Version 1.1

    DOR was defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurred first. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to \<10 mm short axis and the normalization of tumor marker level. PR was defined as \>=30% decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. There was no participant who had event (CR/PR), hence data could not be collected and analyzed for this outcome measure.

    Time frame: From the date of first documented response up to date of first documented PD or death (up to 3.8 months)

  2. Disease Control Rate (DCR) as Per RECIST Version 1.1

    DCR was defined as the percentage of participants achieving CR or PR or stable disease (SD) for at least 11 weeks as defined by RECIST version 1.1. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to \<10 mm short axis and the normalization of tumor marker level. PR was defined as \>=30% decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.

    Time frame: From start of treatment on Day 1 up to 3.8 months

  3. Progression Free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from the date of first dose of study drug until the date of objective disease progression or death by any cause, whichever comes first, based on investigator assessment using RECIST Version 1.1. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.

    Time frame: From start of the treatment (Day 1) until disease progression or death (up to 3.8 months)

  4. Overall Survival (OS)

    OS was defined as the time from the date of first dose of study drug until the date of death due to any cause.

    Time frame: From start of the treatment (Day 1) until death due to any cause (up to 3.8 months)

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as AEs occurring at or after first dose of study drug up to 30 days after last dose or until the start of new anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE version 5.0. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences; Grade 5- Death related to AE. All TEAEs including serious and non-serious events were reported in this outcome measure.

    Time frame: From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)

  6. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Number of participants with clinically significant abnormalities in laboratory parameters (serum chemistry and hematology) were reported. Clinically significant abnormalities were determined based on investigator's discretion.

    Time frame: From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)

  7. Number of Participants With Clinically Significant Abnormalities in Vital Signs Values

    Vital signs assessments included systolic and diastolic blood pressure, heart rate, respiratory rate, pulse rate, body temperature and oxygen saturation. These measurements were taken after the participants had rested for at least 5 minutes in a quiet setting without distractions. Clinical significance of any vital signs was determined based on investigator's discretion.

    Time frame: From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)

  8. Maximum Observed Serum Concentration (Cmax) of Amivantamab

    Cmax was defined as the maximum observed serum concentration of amivantamab. The concentrations of amivantamab were measured using a validated, specific, and sensitive enzyme-linked immunosorbent assay (ELISA) method.

    Time frame: Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  9. Time to Reach Maximum Observed Serum Concentration (Tmax) of Amivantamab

    Tmax was defined as the time to reach maximum observed serum concentration of amivantamab. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  10. Area Under the Serum Concentration Time Curve From Time Zero to Time 168 Hours (h) (AUC [0-168h]) of Amivantamab

    AUC (0-168h) was defined as area under the serum concentration time-curve from time zero to the time point 168 hours. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72 and 168 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  11. Area Under the Serum Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab

    Area under the serum concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval of 336 hours was reported. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  12. Serum Trough Concentrations (Ctrough) of Amivantamab: on Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3

    Ctrough of amivantamab at pre-dose on Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3 were reported. Ctrough was defined as pre-dose serum drug concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose at 0 hour: Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3 (each cycle was of 28 days)

  13. Serum Trough Concentrations (Ctrough) of Amivantamab: on Day 1 of Cycle 3

    Ctrough of amivantamab at pre-dose on Day 1 of Cycle 3 were reported. Ctrough was defined as pre-dose serum drug concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method. As per change in planned analysis, data was not summarized for timepoint where number of participants analyzed were less than 3. Only individual participant data was available and reported.

    Time frame: Pre-dose at 0 hour on Day 1 of Cycle 3 (each cycle was of 28 days)

  14. Terminal Elimination Half-Life (t1/2) of Amivantamab

    Terminal elimination half-life (t1/2) was the time measured for the serum concentration of a drug to decrease by half of its initial concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  15. Accumulation Ratio (AR) of AUC (0-168 h) of Amivantamab

    Accumulation ratio for AUC was calculated as AUC (0-168 h) for Cycle 2 Day 1 divided by AUC (0-168 h) for Cycle 1 Day 1. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

    Time frame: Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72 and 168 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)

  16. Number of Participants With Anti-Amivantamab Antibodies

    Number of participants with anti-amivantamab antibodies were reported. Serum samples were assessed for anti-drug antibodies.

    Time frame: From start of the treatment (Day 1) up to 30 days after the last dose of study drug (up to 3.8 months)

07

Results

Posted Oct 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneAmivantamab Monotherapy (1050/1400 mg)
Started18
Completed5
Not completed13
Withdrew: Study terminated by sponsor13

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment

ORR was defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) as determined by investigator per RECIST version 1.1. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to less than (\<)10 millimeter (mm) short axis and the normalization of tumor marker level. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions.

Time frame:
From start of treatment on Day 1 up to 3.8 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment
Percentage of participantsAmivantamab Monotherapy (1050/1400 mg)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment0.0 (0.0 to 18.5)
SecondaryDuration of Response (DOR) as Per RECIST Version 1.1

DOR was defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurred first. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to \<10 mm short axis and the normalization of tumor marker level. PR was defined as \>=30% decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. There was no participant who had event (CR/PR), hence data could not be collected and analyzed for this outcome measure.

Time frame:
From the date of first documented response up to date of first documented PD or death (up to 3.8 months)

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR) as Per RECIST Version 1.1

DCR was defined as the percentage of participants achieving CR or PR or stable disease (SD) for at least 11 weeks as defined by RECIST version 1.1. As per RECIST version 1.1, CR was defined as disappearance of all extranodal lesions, the regression of all nodal lesions to \<10 mm short axis and the normalization of tumor marker level. PR was defined as \>=30% decrease in the sum of diameters of target lesions, taking as reference baseline sum of diameters of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.

Time frame:
From start of treatment on Day 1 up to 3.8 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) as Per RECIST Version 1.1
Percentage of participantsAmivantamab Monotherapy (1050/1400 mg)
Disease Control Rate (DCR) as Per RECIST Version 1.10.0 (0.0 to 18.5)
SecondaryProgression Free Survival (PFS) as Per RECIST Version 1.1

PFS was defined as the time from the date of first dose of study drug until the date of objective disease progression or death by any cause, whichever comes first, based on investigator assessment using RECIST Version 1.1. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.

Time frame:
From start of the treatment (Day 1) until disease progression or death (up to 3.8 months)
Reported as:
Median · Months
Progression Free Survival (PFS) as Per RECIST Version 1.1
MonthsAmivantamab Monotherapy (1050/1400 mg)
Progression Free Survival (PFS) as Per RECIST Version 1.11.48 (1.41 to 1.51)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose of study drug until the date of death due to any cause.

Time frame:
From start of the treatment (Day 1) until death due to any cause (up to 3.8 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAmivantamab Monotherapy (1050/1400 mg)
Overall Survival (OS)NA (3.84 to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as AEs occurring at or after first dose of study drug up to 30 days after last dose or until the start of new anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE version 5.0. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences; Grade 5- Death related to AE. All TEAEs including serious and non-serious events were reported in this outcome measure.

Time frame:
From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0
ParticipantsAmivantamab Monotherapy (1050/1400 mg)
Grade 15
Grade 29
Grade 33
Grade 40
Grade 51
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Number of participants with clinically significant abnormalities in laboratory parameters (serum chemistry and hematology) were reported. Clinically significant abnormalities were determined based on investigator's discretion.

Time frame:
From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsAmivantamab Monotherapy (1050/1400 mg)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters3
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs Values

Vital signs assessments included systolic and diastolic blood pressure, heart rate, respiratory rate, pulse rate, body temperature and oxygen saturation. These measurements were taken after the participants had rested for at least 5 minutes in a quiet setting without distractions. Clinical significance of any vital signs was determined based on investigator's discretion.

Time frame:
From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs Values
ParticipantsAmivantamab Monotherapy (1050/1400 mg)
Number of Participants With Clinically Significant Abnormalities in Vital Signs Values0
SecondaryMaximum Observed Serum Concentration (Cmax) of Amivantamab

Cmax was defined as the maximum observed serum concentration of amivantamab. The concentrations of amivantamab were measured using a validated, specific, and sensitive enzyme-linked immunosorbent assay (ELISA) method.

Time frame:
Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Mean · Micrograms per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of Amivantamab
Micrograms per milliliter (mcg/mL)Amivantamab Monotherapy (1050/1400 mg)
Cycle 1 Day 1339 ± 57.0
Cycle 2 Day 1711 ± 79.0
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of Amivantamab

Tmax was defined as the time to reach maximum observed serum concentration of amivantamab. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Median · Hours
Time to Reach Maximum Observed Serum Concentration (Tmax) of Amivantamab
HoursAmivantamab Monotherapy (1050/1400 mg)
Cycle 1 Day 127.18 (25.68 to 28.70)
Cycle 2 Day 15.87 (2.27 to 7.75)
SecondaryArea Under the Serum Concentration Time Curve From Time Zero to Time 168 Hours (h) (AUC [0-168h]) of Amivantamab

AUC (0-168h) was defined as area under the serum concentration time-curve from time zero to the time point 168 hours. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72 and 168 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Mean · micrograms*hours/milliliter (mcg*hr/mL)
Area Under the Serum Concentration Time Curve From Time Zero to Time 168 Hours (h) (AUC [0-168h]) of Amivantamab
micrograms*hours/milliliter (mcg*hr/mL)Amivantamab Monotherapy (1050/1400 mg)
Cycle 1 Day 129084 ± 3772
Cycle 2 Day 180434 ± 11319
SecondaryArea Under the Serum Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab

Area under the serum concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval of 336 hours was reported. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Mean · mcg*hr/mL
Area Under the Serum Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab
mcg*hr/mLAmivantamab Monotherapy (1050/1400 mg)
Area Under the Serum Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab117913 ± 19426
SecondarySerum Trough Concentrations (Ctrough) of Amivantamab: on Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3

Ctrough of amivantamab at pre-dose on Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3 were reported. Ctrough was defined as pre-dose serum drug concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose at 0 hour: Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3 (each cycle was of 28 days)
Reported as:
Mean · mcg/mL
Serum Trough Concentrations (Ctrough) of Amivantamab: on Days 8 and 15 of Cycle 1; Day 1 of Cycle 2 and Cycle 4; Day 15 of Cycle 2 and Cycle 3
mcg/mLAmivantamab Monotherapy (1050/1400 mg)
Pre-dose Cycle 1 Day 8145 ± 103
Pre-dose Cycle 1 Day 15229 ± 117
Pre-dose Cycle 2 Day 1326 ± 76.0
Pre-dose Cycle 2 Day 15216 ± 71.3
Pre-dose Cycle 3 Day 1587.7 ± NA
Pre-dose Cycle 4 Day 187.6 ± NA
SecondarySerum Trough Concentrations (Ctrough) of Amivantamab: on Day 1 of Cycle 3

Ctrough of amivantamab at pre-dose on Day 1 of Cycle 3 were reported. Ctrough was defined as pre-dose serum drug concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method. As per change in planned analysis, data was not summarized for timepoint where number of participants analyzed were less than 3. Only individual participant data was available and reported.

Time frame:
Pre-dose at 0 hour on Day 1 of Cycle 3 (each cycle was of 28 days)
Reported as:
Mean · mcg/mL
Serum Trough Concentrations (Ctrough) of Amivantamab: on Day 1 of Cycle 3
mcg/mLAmivantamab Monotherapy (1050/1400 mg)
Participant 1104 ± NA
Participant 2162 ± NA
SecondaryTerminal Elimination Half-Life (t1/2) of Amivantamab

Terminal elimination half-life (t1/2) was the time measured for the serum concentration of a drug to decrease by half of its initial concentration. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose, 0, 2, 6, 24, 72, 168, 240 and 336 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Mean · Hours
Terminal Elimination Half-Life (t1/2) of Amivantamab
HoursAmivantamab Monotherapy (1050/1400 mg)
Terminal Elimination Half-Life (t1/2) of Amivantamab201.3 ± 39.8
SecondaryAccumulation Ratio (AR) of AUC (0-168 h) of Amivantamab

Accumulation ratio for AUC was calculated as AUC (0-168 h) for Cycle 2 Day 1 divided by AUC (0-168 h) for Cycle 1 Day 1. The concentrations of amivantamab were measured using a validated, specific, and sensitive ELISA method.

Time frame:
Pre-dose, 0, 24, 26, 30, 48, 96 and 168 hours post-dose on Day 1 of Cycle 1; pre-dose, 0, 2, 6, 24, 72 and 168 hours post-dose on Day 1 of Cycle 2 (each cycle was of 28 days)
Reported as:
Mean · Ratio
Accumulation Ratio (AR) of AUC (0-168 h) of Amivantamab
RatioAmivantamab Monotherapy (1050/1400 mg)
Accumulation Ratio (AR) of AUC (0-168 h) of Amivantamab2.85 ± 0.46
SecondaryNumber of Participants With Anti-Amivantamab Antibodies

Number of participants with anti-amivantamab antibodies were reported. Serum samples were assessed for anti-drug antibodies.

Time frame:
From start of the treatment (Day 1) up to 30 days after the last dose of study drug (up to 3.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Amivantamab Antibodies
ParticipantsAmivantamab Monotherapy (1050/1400 mg)
Number of Participants With Anti-Amivantamab Antibodies0

Adverse events

Collected over All-cause mortality: From screening up to 4.8 months; Serious AEs and Other AEs: From start of the treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (up to 3.8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amivantamab Monotherapy (1050/1400 mg)5/18 (27.8%)4/18 (22.2%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventAmivantamab Monotherapy (1050/1400 mg)
AscitesGastrointestinal disorders3/18
DiarrhoeaGastrointestinal disorders1/18
Tumour HaemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/18
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAmivantamab Monotherapy (1050/1400 mg)
HypoalbuminaemiaMetabolism and nutrition disorders11/18
RashSkin and subcutaneous tissue disorders11/18
Infusion Related ReactionInjury, poisoning and procedural complications9/18
Dermatitis AcneiformSkin and subcutaneous tissue disorders6/18
Alanine Aminotransferase IncreasedInvestigations5/18
Aspartate Aminotransferase IncreasedInvestigations5/18
LeukopeniaBlood and lymphatic system disorders4/18
NeutropeniaBlood and lymphatic system disorders4/18
HaematuriaRenal and urinary disorders4/18
AnaemiaBlood and lymphatic system disorders3/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Amivantamab Monotherapy (1050/1400 mg)
<=18 years0
Between 18 and 65 years15
>=65 years3
Age, Continuous
Age, Continuous(Years)Amivantamab Monotherapy (1050/1400 mg)
Mean49.9 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Amivantamab Monotherapy (1050/1400 mg)
Female2
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Amivantamab Monotherapy (1050/1400 mg)
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Amivantamab Monotherapy (1050/1400 mg)
American Indian or Alaska Native0
Asian18
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Amivantamab Monotherapy (1050/1400 mg)
CHINA18
08

Study locations

13 sites
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • The First Hospital of Jilin University
    Chang Chun Shi, 130021, China
  • The Third Xiangya Hospital, Central South University
    Changsha, 410013, China
  • West China Hospital
    Chengdu, 610041, China
  • Chongqing Cancer Hospital
    Chong Qing, 400033, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, 116023, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fu Zhou Shi, 350025, China
  • Nanfang Hospital
    Guang Zhou Shi, 510515, China
  • Zhejiang University First Hospital
    Hang Zhou Shi, 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • The Second Affiliatde Hospital To Nanchang University
    Nan Chang Shi, 330030, China
  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, 430030, China
  • Xi An International Medical Center Hospital
    XI An, 710100, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Oct 2023, 10 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Dec 8, 2022
Primary completionActual
Oct 10, 2023
CompletionActual
Oct 10, 2023
Results first posted
Oct 30, 2024
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05653427
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Dec 8, 2022
Primary completion
Oct 10, 2023
Completion
Oct 10, 2023
Results posted
Oct 30, 2024
Last update
Jan 13, 2025

Study contacts

Janssen Research & Development, LLC Clinical trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amivantamab

Start the discussion